Bicycle Therapeutics Equity 2024

Bicycle Therapeutics Aktienanalyse

What does Bicycle Therapeutics do?

Bicycle Therapeutics PLC is a British biotechnology company specializing in the development of innovative drugs for the treatment of cancer and other diseases. The company was founded in 2009 by Sir Greg Winter, John McCafferty, and Sir Tom Blundell. They discovered a new class of molecules called Bicycles, which are small enough to penetrate the human body but large enough to selectively bind to cells and tissues and influence their biological functions. Bicycles are based on a technology called phage display, which allows for the targeted identification and isolation of molecules with specific properties. The business model of Bicycle Therapeutics revolves around using Bicycles as drug candidates for the development of new medications. The company collaborates with leading pharmaceutical and biotechnology companies to jointly develop new therapies, focusing primarily on cancer treatment due to the high demand for targeted therapies in this field. Bicycle Therapeutics has various divisions dedicated to the development of drugs for specific types of cancer. Immunoncology is one such division, which focuses on mobilizing the body's immune system to fight cancer. Another division, Targeted Payloads, concentrates on developing medications that specifically attack and destroy cancer cells. The company offers a range of products developed based on Bicycles, including therapeutic antibodies that selectively target and destroy cancer cells, as well as diagnostics for the early detection and diagnosis of cancer. One example of Bicycle Therapeutics' product is BT1718, a therapeutic antibody that specifically targets the membrane protein 5 (MP5). MP5 is expressed on the surface of various cancer cells and is therefore a promising target for cancer therapy. BT1718 has shown promising results in clinical studies involving patients with various types of cancer. Another example is BT5528, a targeted payload that targets the EphA2 receptor. EphA2 is expressed on the surface of different cancer cells and plays a crucial role in tumor progression. BT5528 is a molecule that specifically binds to EphA2 and releases a payload that attacks and destroys cancer cells. The product is currently in clinical development. Overall, Bicycle Therapeutics is a promising biotechnology company specializing in the development of innovative drugs for the treatment of cancer and other diseases. The company has a unique technology platform and collaborates with leading pharmaceutical and biotechnology companies to develop new therapies. With products like BT1718 and BT5528, Bicycle Therapeutics has already achieved promising results and remains an important player in the field of cancer therapy. Bicycle Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Equity Details

Analyzing Bicycle Therapeutics's Equity

Bicycle Therapeutics's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Bicycle Therapeutics's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Bicycle Therapeutics's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Bicycle Therapeutics's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Bicycle Therapeutics’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Bicycle Therapeutics stock

What is the equity of Bicycle Therapeutics this year?

Bicycle Therapeutics has equity of 370.93 M USD this year.

What was the equity of Bicycle Therapeutics compared to the previous year?

The equity of Bicycle Therapeutics has increased/decreased by 36.98% increased compared to the previous year.

What impact does a high equity have on investors of Bicycle Therapeutics?

A high equity is advantageous for investors of Bicycle Therapeutics as it is an indicator of the company's financial stability and its ability to manage risks and challenges.

What impact does low equity have on investors of Bicycle Therapeutics?

A low equity can be a risk for investors of Bicycle Therapeutics, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.

How does an increase in equity of Bicycle Therapeutics affect the company?

An increase in equity of Bicycle Therapeutics can strengthen the company's financial position and improve its ability to make investments in the future.

How does a reduction in the equity of Bicycle Therapeutics affect the company?

A reduction in equity of Bicycle Therapeutics can affect the financial situation of the company and lead to a higher dependence on debt capital.

What are some factors that influence the equity of Bicycle Therapeutics?

Some factors that can affect the equity of Bicycle Therapeutics include profits, dividend payments, capital increases, and acquisitions.

Why is the equity of Bicycle Therapeutics so important for investors?

The equity of Bicycle Therapeutics is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.

What strategic measures can Bicycle Therapeutics take to change the equity?

To change equity, Bicycle Therapeutics can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.

How much dividend does Bicycle Therapeutics pay?

Over the past 12 months, Bicycle Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Bicycle Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of Bicycle Therapeutics?

The current dividend yield of Bicycle Therapeutics is .

When does Bicycle Therapeutics pay dividends?

Bicycle Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Bicycle Therapeutics?

Bicycle Therapeutics paid dividends every year for the past 0 years.

What is the dividend of Bicycle Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Bicycle Therapeutics located?

Bicycle Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Bicycle Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Bicycle Therapeutics from 9/26/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/26/2024.

When did Bicycle Therapeutics pay the last dividend?

The last dividend was paid out on 9/26/2024.

What was the dividend of Bicycle Therapeutics in the year 2023?

In the year 2023, Bicycle Therapeutics distributed 0 USD as dividends.

In which currency does Bicycle Therapeutics pay out the dividend?

The dividends of Bicycle Therapeutics are distributed in USD.